Skip to main content

Cingulate Inc.

CINGW
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001862150

No open-market purchases or sales by Cingulate Inc. insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $1.88K in total; no superinvestor holds it.

Other share classesCING

Key figures

Insider buysOpen market, last 90 days
0
Insider sellsOpen market, last 90 days
0
13F holdersQ2 2026, +4 vs. previous quarter
8
13F valueReported value at the end of Q2 2026
$1.88K
Superinvestors holdingAt the end of Q2 2026
0

Price chart

Superinvestors holding CINGW, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding CINGW at the end of Q2 2026.

Latest insider trades

Open-market purchases and sales by Cingulate Inc. insiders from Form 4, newest first.

See all insider trades
Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jun 8, 2026 (view filing)7:02 PM ETFeb 13115 daysLateHargroves Thomas JeffreyDirectorPPurchase+97.3K$5.04+$490.3K+50,664.6%97.5K after
Jun 8, 2026 (view filing)7:02 PM ETFeb 13115 daysLateHargroves Thomas JeffreyDirectorPPurchase+77.8K$0.10+$7.78K–77.8K afterDerivative
Feb 10, 2026 (view filing)7:00 PM ETFeb 64 daysWerth Peter J.DirectorPPurchase+19.5K$5.04+$98.1K+19.9%117.4K after
Feb 10, 2026 (view filing)7:00 PM ETFeb 64 daysWerth Peter J.DirectorPPurchase+15.6K$0.10+$1.56K–15.6K afterDerivative
Feb 10, 2026 (view filing)7:00 PM ETFeb 64 daysCallahan Jennifer L.SVP and CFOPPurchase+4.86K$5.04+$24.5K+2,494.4%5.06K after
Feb 10, 2026 (view filing)7:00 PM ETFeb 64 daysCallahan Jennifer L.SVP and CFOPPurchase+3.89K$0.10+$389.1–3.89K afterDerivative
Feb 10, 2026 (view filing)7:00 PM ETFeb 64 daysSchaffer Shane J.Chief Executive OfficerPPurchase+6.81K$5.04+$34.3K+202.3%10.2K after
Feb 10, 2026 (view filing)7:00 PM ETFeb 64 daysSchaffer Shane J.Chief Executive OfficerPPurchase+5.45K$0.10+$544.7–5.45K afterDerivative
Feb 10, 2026 (view filing)7:00 PM ETFeb 64 daysBrams MatthewEVP and Chief Medical OfficerPPurchase+1.95K$5.04+$9.81K+71.8%4.66K after
Feb 10, 2026 (view filing)7:00 PM ETFeb 64 daysBrams MatthewEVP and Chief Medical OfficerPPurchase+1.56K$0.10+$155.6–1.56K afterDerivative

Top 10 13F holders, Q2 2026

The largest institutional positions in Cingulate Inc. at the end of Q2 2026; share changes are against Q1 2026.

See all 8 holders
Institutions holding CINGW in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Captrust Financial Advisors35,200$6720.00%+20,000+131.6%Added
MAI Capital Management26,021$4970.00%+26,021New
Susquehanna International Group, LLP23,080$4410.00%+23,080New
Two Sigma Securities, LLC10,918$2090.00%+10,918New
GoalVest Advisory LLC3,000$570.00%00.0%Unchanged
Toronto Dominion Bank100$20.00%+100New
HRT Financial LP13,224$00.00%+13,224New
Virtu Financial LLC12,626$00.00%+12,626New